Signaturefd, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 139 shares of MDGL stock, worth $30,163. This represents 0.0% of its overall portfolio holdings.

Number of Shares

139

Previous 145 4.14%

Holding current value

$30,163

Previous $40,000 27.5%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$212.22 - $292.96 $1,273 - $1,757	-6 Reduced 4.14%	139 $29,000
Q2 2024 Jul 29, 2024	BUY	$193.33 - $291.99 $7,539 - $11,387	39 Added 36.79%	145 $40,000
Q1 2024 May 03, 2024	BUY	$171.37 - $283.23 $685 - $1,132	4 Added 3.92%	106 $28,000
Q4 2023 Jan 31, 2024	BUY	$120.4 - $237.13 $1,204 - $2,371	10 Added 10.87%	102 $23,000
Q3 2023 Nov 03, 2023	BUY	$146.04 - $225.78 $7,740 - $11,966	53 Added 135.9%	92 $13,000
Q4 2022 Jan 27, 2023	BUY	$58.39 - $296.54 $2,277 - $11,565	39 New	39 $11,000
Q1 2022 May 02, 2022	SELL	$55.89 - $101.89 $3,018 - $5,502	-54 Closed	0 $0
Q4 2021 Jan 25, 2022	BUY	$72.34 - $95.09 $3,617 - $4,754	50 Added 1250.0%	54 $5,000
Q3 2021 Oct 28, 2021	SELL	$78.35 - $105.02 $2,585 - $3,465	-33 Reduced 89.19%	4 $0
Q2 2021 Jul 26, 2021	SELL	$97.2 - $137.59 $777 - $1,100	-8 Reduced 17.78%	37 $4,000
Q1 2021 Apr 30, 2021	BUY	$108.54 - $125.2 $4,884 - $5,634	45 New	45 $5,000
Q3 2020 Nov 03, 2020	SELL	$99.78 - $124.21 $698 - $869	-7 Closed	0 $0
Q2 2020 Jul 30, 2020	BUY	$60.13 - $125.71 $420 - $879	7 New	7 $1,000

Others Institutions Holding MDGL

# of Institutions

297

Shares Held

21.9M

Call Options Held

757K

Put Options Held

370K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $3.71B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account